A coronavirus vaccine candidate being developed by the University of Oxford has successfully triggered a strong immune response in trials involving 1,077 people. Scientific journal The Lancet published the hugely promising results of Phase I/II trials and they have raised hopes that a safe, effective and accessible vaccine will be attainable to help end the pandemic. The trial provoked a T cell response within 14 days of vaccination and an antibody response within 28 days.

Even ahead of the tests, there have been commitments to supply over 2 billion doses of the vaccine to the United Kingdom, the United States, Europe's Inclusive Vaccines Alliance,  the Coalition for Epidemic Preparedness, Gavi the Vaccine Alliance and the Serum Institute of India. Vaccines generally take years to develop but the University of Oxford have been working on their current project at an unprecedented pace. It is one of over 140 Covid-19 vaccine candidates listed by the World Health Organization, according to The Guardian and several are already in advanced testing.

Read the full story in Statista.com. And in Monday’s Data Feed, look for an infographic on the history of vaccines.